Granted Patent B2

US 12,241,128 · App. 18/441,187 · Granted Mar 4, 2025

Inventors: Stefanie Ann Ward Mortimer (Morgan Hill, CA); Amirali Talasaz (Atherton, CA); Darya Chudova (San Jose, CA); Helmy Eltoukhy (Atherton, CA)

Assignee: Guardant Health, Inc.

C12Q1/6886C12M1/00C12M1/34C12Q1/6806C12Q1/6855C12Q1/6869G01N33/57407G16B20/20G16B30/10G16H50/20G16H50/30C12Q2600/118C12Q2600/154C12Q2600/156C12Q2600/158C12Q2600/166

Abstract

Claims (25)

1. A method for detecting a presence or absence of residual disease in a subject having previously received a treatment for cancer, the method comprising:

(a) ligating adapters to a plurality of cell-free deoxyribonucleic acid (cfDNA) molecules from a blood sample from the subject to produce adapter-ligated polynucleotides, wherein the blood sample was obtained from the subject after the treatment for cancer;

(b) amplifying a plurality of the adapter-ligated polynucleotides to produce amplified polynucleotides;

(c) enriching the amplified polynucleotides for a panel of targeted genomic regions by performing amplification-based enrichment, wherein the panel comprises no more than 20 genomic regions;

(d) sequencing a plurality of enriched cfDNA to generate sequencing data comprising sequencing reads, wherein the sequencing is performed at a depth of at least 50,000 reads per base; and

(e) determining a presence or absence of one or more genetic variants in the cfDNA molecules from the sequencing data to detect the presence or absence of residual disease in the subject.

2. The method of claim 1 , wherein the cfDNA molecules are end-repaired and/or A-tailed prior to the ligating in (a).

3. The method of claim 1 , wherein the genomic regions in the sequencing panel have a size from about 0.1 kb to about 5 kb.

4. The method of claim 1 , wherein the genomic regions in the sequencing panel have a size of about 1 kb or less.

5. The method of claim 1 , wherein the sequencing is massively parallel sequencing that sequences at least 10 million polynucleotide molecules.

6. The method of claim 1 , wherein the sequencing data comprises at least 1 billion, 1.1 billion, 1.2 billion, 1.5 billion, 2 billion, 2.5 billion, 3 billion, 3.5 billion, 4 billion, 4.5 billion, 5 billion, 5.5 billion, 6 billion, 6.5 billion, 7 billion, 8 billion, 9 billion or 10 billion base pairs.

7. The method of claim 1 , wherein a read budget is selected that identifies the total number of base reads to be allocated to the sample, wherein the sample comprises a predetermined amount of DNA.

8. The method of claim 1 , wherein the sequencing is performed at a depth of at least 100,000 reads per base.

9. The method of claim 1 , wherein the sequencing is performed at a depth of at least 120,000 reads per base.

10. The method of claim 1 , wherein the reads per base represent at least 5,000 original cfDNA molecules in the sample.

11. The method of claim 1 , wherein the treatment for cancer comprises surgical treatment, radiation treatment, chemotherapy, targeted cancer therapeutics or a cancer immunotherapy.

12. The method of claim 11 , wherein the surgical treatment comprises removal of cancer tissue.

13. The method of claim 1 , wherein the subject does not have a cancer that is detectable by imaging methods.

14. The method of claim 13 , wherein the imaging method is positron emission tomography scan, magnetic resonance imaging, X-ray, computerized axial tomography scan, ultrasound, or a combination thereof.

15. The method of claim 1 , wherein the cancer is colorectal cancer, ovarian cancer, lung cancer, pancreatic cancer, or liver cancer.

16. The method of claim 1 , wherein the determining the presence or absence of one or more genetic variants comprises aligning sequencing reads to a reference sequence.

17. The method of claim 16 , wherein the determining the presence or absence of one or more genetic variants comprises determining a consensus sequence from sequence reads obtained from the sequence data to reduce errors from amplification or sequencing.

18. The method of claim 1 , wherein a frequency of nucleotides in the sample is determined by comparing it to a frequency of germline DNA from the subject.

19. The method of claim 1 , wherein one or more of the genomic regions in the panel are selected based on having a frequency of a tumor marker that is significantly greater in sampled tumor tissue than found in a given background population.

20. The method of claim 1 , further comprising detecting mutation distributions for each of one or more driver mutations, wherein the mutation distribution for each of the one or more driver mutations is detected with a correlation of at least 0.99 to a mutation distribution of the driver mutation detected in a cohort of the subject by tissue genotyping.

Assignments (1)

Continuity (16)

References Cited (167)

Cited By (2)

US 12,571,053 US 12,571,055